Central Health

PR Newswire | April 14, 2020

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM070...

INDUSTRIAL IMPACT

FEN Industries | February 22, 2022

FEN announced today that it has earned the U.S. Department of Agriculture (USDA) Certified Biobased Product label. The product, Terreplenish®, has 97% biobased content. Third-party verification for a product's biobased content is administered through the USDA BioPreferred Program, an initiative created by the Farm Bill. The primary goal of the BioPreferred Program is to increase the development, purchase, and use of biobased products. Biobased products have ...

CELL AND GENE THERAPY

Genscript Biotech Corporation | September 23, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

CELL AND GENE THERAPY

Kaneka Eurogentec | February 23, 2022

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...